...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith trial partners

KBC - I was never saying that money would or should be directed toward RVX, only stating the only way it could legally. If it was a good investment so in the shareholders interest and Zenith had looked after its shareholders and still had cash to do it, that is the only way it could happen. That isn't how things are and I don't expect to be. 

Share
New Message
Please login to post a reply